Leuprolide (Lupron, Lupron Depot)

Category:

  • Hormonal

Description:

  • Luteinizing hormone-releasing hormone (LH-RH) agonist, inhibits gonadotropin secretion

Indications:

  • Advanced prostatic cancer

  • Central precocious puberty

  • Endometriosis

  • Uterine fibroids

Contraindications:

  • Pregnancy and lactation

  • Undiagnosed vaginal bleeding

  • 30mg depot formulation is contraindicated in women

Precautions:

  • Pregnancy category X

  • Increase in occurrence of disease (prostatic and endometriosis) during initial phases of treatment.

  • May cause bone density changes

Adverse Reactions (Side Effects):

  • ECG changes and ischemia (19.4%)

  • Injection site irritation (13.8%)

  • Edema (12.2%)

  • Hot flashes and sweating (47-84%)

  • Generalized pain (6-32%)

  • Decrease in testicular size  

Dosage:

  • Administered by injection

  • Advanced prostatic cancer: 1mg SQ daily or 7.5mg IM monthly or 22.5mg IM every three months or 30mg IM every four months

  • Central precocious puberty: individualize dose per patient based on weight

  • < 25kg = 7.5mg IM every four weeks

  • 25-37.5kg = 11.25mg IM every four weeks

  • >37.5kg = 15mg IM every four weeks

  • Endometriosis: 3.75mg IM monthly or 11.25mg IM every three months

  • Uterine fibroids: recommended therapy less than 3 months

  • 3.75mg IM monthly or 11.25mg IM once for three months

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300  


OB-GYN 101: Introductory Obstetrics & Gynecology
© 2003, 2004, 2005 Medical Education Division, Brookside Associates, Ltd.
All rights reserved

Contents · Introduction · Learning Objectives · Clinical Issues · Procedures  · Library · Pharmacy · Lab · Chest X-ray · Ultrasound · Videos · Forms · Progress Notes · Facts Cards · Students · Search · Feedback · About Us